Prader-Willi syndrome (PWS) is a complex neurodevelopmental genetic disorder characterized by severe hypotonia and feeding difficulties in infancy with gradual development of hyperphagia and morbid obesity in early childhood, as well as development of short stature, scoliosis, and maladaptive and compulsive behaviors.
Tests generally appear in the order most useful for common clinical situations
| Test name: Angelman Syndrome and Prader-Willi Syndrome by Methylation |
| ARUP #: 2005077 |
| Methodology: Methylation Sensitive Polymerase Chain Reaction/Fluorescence Monitoring |
| Use: Identify microdeletion in chromosome 15q11-q13 in individuals who are symptomatic or are suspected of having PWS Clinical sensitivity for PWS is greater than or equal to 99% |
| Limitations: Molecular mechanisms not affecting methylation patters leading to PWS are not assessed |
| Test name: Chromosome FISH, Metaphase |
| ARUP #: 2002299 |
| Methodology: Fluorescence in situ Hybridization |
| Use: Tests for microdeletion 15q11-q13 in individuals known or suspected to have PWS Indicate names of probes needed for testing |
| Limitations: PWS caused by uniparental disomy or imprinting center defects will not be detected; therefore, it is recommended that the methylation sensitive polymerase chain reaction/fluorescent monitoring test be performed instead of the FISH assay Clinical sensitivity for PWS is 70% |
| Test name: Angelman Syndrome (UBE3A) Sequencing |
| ARUP #: 2005564 |
| Methodology: Polymerase Chain Reaction/Sequencing |
| Comments: Confirm diagnosis of Angelman syndrome in individuals with normal DNA methylation test |